- It’s estimated that up to 80% of women in menopause will experience vasomotor symptoms, also known as hot flashes.
- Federal regulators have now approved a new drug, Veozah, to treat this particular menopausal symptom.
- Experts say the oral medication should be relief to many women.
- They also note there are lifestyle factors that also can help ease hot flashes, including a healthy diet and adequate sleep.
The Food and Drug Administration (FDA) has
It is the first medicine of its kind (neurokinin 3) to be approved for treating vasomotor symptoms. It’s expected that the drug will be available in retail pharmacies in about three weeks.
“Veozah is a new drug based on solid research and has FDA approval,” said Dr. Monte Swarup, FACOG, an OB/GYN in Chandler, Arizona, and founder of the leading vaginal health information site Vaginal Health Hub.
“It’s an oral medication for treating menopause symptoms such as hot flashes and vasomotor symptoms,” he told Medical News Today.
There were two phase 3 studies that led up to the FDA approval.
The mean age of the participants was 54. The subjects were menopausal women with one of the following situations:
The first trial included 522 women. In the second trial there were 500 participants.
The women experienced an average of seven moderate to severe vasomotor symptoms.
Participants were randomized to receive either a 45 mg dose of Veozah or a placebo. In both studies, after 12 weeks, the women receiving a placebo were re-randomized to Veozah to study the medicine’s safety further.
The researchers looked at the frequency and severity of hot flashes at weeks 4 and 12 in both studies. For the frequency of symptoms, they reportedly a clinically meaningful reduction. For severity, they noted a statistically significant decrease.
“Since Veovah is ‘the first drug of its kind’ to be FDA…
Read the full article here